Evolus, Inc.(EOLS)

Drug Manufacturers - Specialty & Generic · Newport Beach, CA

$7.38-0.09 (-1.20%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T22:31:43.836Z.

Stored calculation inputs

Calculation as of: 2026-10-06T22:31:43.836Z.

Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 486,008,062
Total debt · period ending 2026-06-30: 164,804,000
Cash · period ending 2026-06-30: 45,170,000
TTM operating income · period ending 2026-06-30: -23,196,000

FMP input reference: c1a6838803f42d6ea125a2cca62df7e150df7eb7d5f2d1fff74d5c1a91b3d340

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

EOLS EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

EOLS Competitors' EV/EBIT Ratio

EOLS

Evolus, Inc.

Current

Market Cap

$486.01M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PBYI

Puma Biotechnology, Inc.

vs EOLS

Market Cap

$483.54M

EV/EBIT Ratio

14.85x

TTM Avg

10.51x

3Y Avg

8.16x

5Y Avg

8.11x

CTNM

Contineum Therapeutics, Inc.

vs EOLS

Market Cap

$475.91M

EV/EBIT Ratio

N/A

TTM Avg

5.92x

3Y Avg

17.76x

5Y Avg

17.76x

OCS

Oculis Holding AG

vs EOLS

Market Cap

$498.52M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DRUG

Bright Minds Biosciences Inc.

vs EOLS

Market Cap

$472.23M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ARVN

Arvinas, Inc.

vs EOLS

Market Cap

$471.65M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CERS

Cerus Corporation

vs EOLS

Market Cap

$471.57M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

TCMD

Tactile Systems Technology, Inc.

vs EOLS

Market Cap

$500.52M

EV/EBIT Ratio

12.70x

TTM Avg

18.96x

3Y Avg

18.37x

5Y Avg

48.35x

BLSM

BlossomHill Therapeutics, Inc.

vs EOLS

Market Cap

$502.81M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

TKNO

Alpha Teknova, Inc.

vs EOLS

Market Cap

$469.12M

EV/EBIT Ratio

N/A

TTM Avg

197.32x

3Y Avg

197.32x

5Y Avg

197.32x

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Evolus, Inc. (EOLS)	$486.01M	N/A	N/A	N/A	N/A
Puma Biotechnology, Inc. (PBYI)vs ›	$483.54M	14.85x	10.51x	8.16x	8.11x
Contineum Therapeutics, Inc. (CTNM)vs ›	$475.91M	N/A	5.92x	17.76x	17.76x
Oculis Holding AG (OCS)vs ›	$498.52M	N/A	N/A	N/A	N/A
Bright Minds Biosciences Inc. (DRUG)vs ›	$472.23M	N/A	N/A	N/A	N/A
Arvinas, Inc. (ARVN)vs ›	$471.65M	N/A	N/A	N/A	N/A
Cerus Corporation (CERS)vs ›	$471.57M	N/A	N/A	N/A	N/A
Tactile Systems Technology, Inc. (TCMD)vs ›	$500.52M	12.70x	18.96x	18.37x	48.35x
BlossomHill Therapeutics, Inc. (BLSM)vs ›	$502.81M	N/A	N/A	N/A	N/A
Alpha Teknova, Inc. (TKNO)vs ›	$469.12M	N/A	197.32x	197.32x	197.32x

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/EBIT Ratio: N/A

EOLS EV/EBIT Ratio Metrics

EOLS Competitors' EV/EBIT Ratio

EV/EBIT Ratio Formula & Definition

Related Metrics